These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 27641943)

  • 1. Integrating cardiomyocytes from human pluripotent stem cells in safety pharmacology: has the time come?
    Sala L; Bellin M; Mummery CL
    Br J Pharmacol; 2017 Nov; 174(21):3749-3765. PubMed ID: 27641943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic drug-induced effects on contractile motion properties and cardiac biomarkers in human induced pluripotent stem cell-derived cardiomyocytes.
    Kopljar I; De Bondt A; Vinken P; Teisman A; Damiano B; Goeminne N; Van den Wyngaert I; Gallacher DJ; Lu HR
    Br J Pharmacol; 2017 Nov; 174(21):3766-3779. PubMed ID: 28094846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Moving beyond the comprehensive in vitro proarrhythmia assay: Use of human-induced pluripotent stem cell-derived cardiomyocytes to assess contractile effects associated with drug-induced structural cardiotoxicity.
    Yang X; Papoian T
    J Appl Toxicol; 2018 Sep; 38(9):1166-1176. PubMed ID: 29484688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An impedance-based approach using human iPSC-derived cardiomyocytes significantly improves in vitro prediction of in vivo cardiotox liabilities.
    Koci B; Luerman G; Duenbostell A; Kettenhofen R; Bohlen H; Coyle L; Knight B; Ku W; Volberg W; Woska JR; Brown MP
    Toxicol Appl Pharmacol; 2017 Aug; 329():121-127. PubMed ID: 28546047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advancing Cardiovascular Drug Screening Using Human Pluripotent Stem Cell-Derived Cardiomyocytes.
    Oh J; Kwon OB; Park SW; Kim JW; Lee H; Kim YK; Choi EJ; Jung H; Choi DK; Oh BJ; Min SH
    Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39063213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of Cardiotoxicity With Stem Cell-based Strategies.
    Stella Stoter AM; Hirt MN; Stenzig J; Weinberger F
    Clin Ther; 2020 Oct; 42(10):1892-1910. PubMed ID: 32938533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. hiPSC-CM Monolayer Maturation State Determines Drug Responsiveness in High Throughput Pro-Arrhythmia Screen.
    da Rocha AM; Campbell K; Mironov S; Jiang J; Mundada L; Guerrero-Serna G; Jalife J; Herron TJ
    Sci Rep; 2017 Oct; 7(1):13834. PubMed ID: 29061979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Probing flecainide block of I
    Geng L; Kong CW; Wong AOT; Shum AM; Chow MZY; Che H; Zhang C; Yau KL; Chan CW; Keung W; Li RA
    Toxicol Lett; 2018 Sep; 294():61-72. PubMed ID: 29758359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human Heart Cardiomyocytes in Drug Discovery and Research: New Opportunities in Translational Sciences.
    Abi-Gerges N; Miller PE; Ghetti A
    Curr Pharm Biotechnol; 2020; 21(9):787-806. PubMed ID: 31820682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-Content Electrophysiological Analysis of Human Pluripotent Stem Cell-Derived Cardiomyocytes (hPSC-CMs).
    Kong CW; Geng L; Li RA
    Methods Mol Biol; 2018; 1722():185-194. PubMed ID: 29264806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Electrophysiological characteristics and pharmacological sensitivity of two lines of human induced pluripotent stem cell derived cardiomyocytes coming from two different suppliers.
    Goineau S; Castagné V
    J Pharmacol Toxicol Methods; 2018; 90():58-66. PubMed ID: 29274391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Trial in a Dish: Using Patient-Derived Induced Pluripotent Stem Cells to Identify Risks of Drug-Induced Cardiotoxicity.
    Lam CK; Wu JC
    Arterioscler Thromb Vasc Biol; 2021 Mar; 41(3):1019-1031. PubMed ID: 33472401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening drug-induced arrhythmia [corrected] using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays.
    Navarrete EG; Liang P; Lan F; Sanchez-Freire V; Simmons C; Gong T; Sharma A; Burridge PW; Patlolla B; Lee AS; Wu H; Beygui RE; Wu SM; Robbins RC; Bers DM; Wu JC
    Circulation; 2013 Sep; 128(11 Suppl 1):S3-13. PubMed ID: 24030418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative analysis of media effects on human induced pluripotent stem cell-derived cardiomyocytes in proarrhythmia risk assessment.
    Schocken D; Stohlman J; Vicente J; Chan D; Patel D; Matta MK; Patel V; Brock M; Millard D; Ross J; Strauss DG; Blinova K
    J Pharmacol Toxicol Methods; 2018; 90():39-47. PubMed ID: 29155283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CSAHi study: Detection of drug-induced ion channel/receptor responses, QT prolongation, and arrhythmia using multi-electrode arrays in combination with human induced pluripotent stem cell-derived cardiomyocytes.
    Kitaguchi T; Moriyama Y; Taniguchi T; Maeda S; Ando H; Uda T; Otabe K; Oguchi M; Shimizu S; Saito H; Toratani A; Asayama M; Yamamoto W; Matsumoto E; Saji D; Ohnaka H; Miyamoto N
    J Pharmacol Toxicol Methods; 2017; 85():73-81. PubMed ID: 28163191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiotoxicity screening with simultaneous optogenetic pacing, voltage imaging and calcium imaging.
    Dempsey GT; Chaudhary KW; Atwater N; Nguyen C; Brown BS; McNeish JD; Cohen AE; Kralj JM
    J Pharmacol Toxicol Methods; 2016; 81():240-50. PubMed ID: 27184445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinase inhibitor-induced cardiotoxicity assessed in vitro with human pluripotent stem cell derived cardiomyocytes.
    Xian HQ; Blanco C; Bonham K; Snodgrass HR
    Toxicol Appl Pharmacol; 2022 Feb; 437():115886. PubMed ID: 35041852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arrhythmia Mechanisms in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    Paci M; Penttinen K; Pekkanen-Mattila M; Koivumäki JT
    J Cardiovasc Pharmacol; 2020 Dec; 77(3):300-316. PubMed ID: 33323698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of Human Pluripotent Stem Cell Derived-Cardiomyocytes to Study Drug-Induced Cardiotoxicity.
    Maillet A; Tan KP; Brunham LR
    Curr Protoc Toxicol; 2017 Aug; 73():22.5.1-22.5.22. PubMed ID: 28777443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The roles of human induced pluripotent stem cell-derived cardiomyocytes in drug discovery: managing in vitro safety study expectations.
    Gintant G; Traebert M
    Expert Opin Drug Discov; 2020 Jun; 15(6):719-729. PubMed ID: 32129680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.